Table 1 Patient characteristics
Characteristics | All (n=59) | Brachytherapy group (n=34) | Control group (n=25) | P value |
|---|---|---|---|---|
Age (year) | 58.71±13.26 | 60.79±12.56 | 55.88±13.90 | 0.161 |
Sex (male/female) | 0.396 | |||
male | 39 (66.1%) | 24 (70.6%) | 15 (60.0%) | |
female | 20 (33.9%) | 10 (29.4%) | 10 (40.0%) | |
Location of obstruction | 0.687 | |||
Hilar bile duct | 52 (88.1%) | 29 (85.3%) | 23 (92.0%) | |
Middle and distal bile duct | 7 (11.9%) | 5 (14.7%) | 2 (8.0%) | |
Etiology | 0.063 | |||
HCC | 14 (23.7%) | 9 (26.5%) | 5 (20.0%) | |
Cholangiocarcinoma | 22 (37.3%) | 16 (47.1%) | 6 (24.0%) | |
Metastatic cancer | 23 (39.0%) | 9 (26.4%) | 14 (56.0%) | |
Bismuth type | 0.149 | |||
II | 5 (8.5%) | 4 (11.8%) | 1 (4%) | |
III | 7 (11.9%) | 6 (17.6%) | 1 (4%) | |
IV | 47 (79.6%) | 24 (70.6%) | 23 (92%) | |
ECOG | 0.643 | |||
1 | 42 (71.2%) | 25 (73.5%) | 17 (68.0%) | |
2 | 17 (28.8%) | 9 (26.5%) | 8 (32.0%) | |
Obstruction length (cm) | 3.24±0.69 | 3.22±0.69 | 3.26±0.70 | 0.817 |
Stent number | 0.166 | |||
one | 10 (16.9%) | 8 (23.5%) | 2 (8.0%) | |
two | 49 (83.1%) | 26 (76.5%) | 23 (92.0%) | |
Systemic anti-tumor therapy | 0.154 | |||
Yes | 15 (25.4%) | 11 (32.4%) | 4 (16.0%) | |
No | 44 (74.6%) | 23 (67.6%) | 21 (84%) |